Table 2. Disease-free survival based on surgical–pathological factors.
| |
|
Univariate |
Multivariate 1 |
Multivariate 2 |
|||
|---|---|---|---|---|---|---|---|
| Five-year (%) | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Histology |
|
|
0.004 |
|
<0.001 |
|
<0.001 |
| SCC | 81.9% | 1 | 1 | 1 | |||
| AC/ AS |
72.0% |
1.79 (1.20–2.68) |
|
3.40 (2.23–5.20) |
|
3.36 (2.20–5.14) |
|
| Lymph node metastasis |
|
|
<0.001 |
|
<0.001 |
|
<0.001 |
| No | 89.6% | 1 | 1 | 1 | |||
| Yes |
49.4% |
6.54 (4.33–9.89) |
|
3.88 (2.41–6.24) |
|
4.19 (2.64–6.65) |
|
| Parametria invasion |
|
|
<0.001 |
|
0.41 |
|
|
| No | 84.1% | 1 | 1 | ||||
| Yes |
58.7% |
3.30 (2.20–4.95) |
|
1.21 (0.77–1.92) |
|
|
|
| Marginal status |
|
|
<0.001 |
|
0.05 |
|
0.031 |
| Negative | 80.1% | 1 | 1 | 1 | |||
| Positive |
50.0% |
4.19 (2.18–8.07) |
|
1.99 (1.00–3.95) |
|
2.11 (1.07–4.17) |
|
| LVSI |
|
|
<0.001 |
|
<0.001 |
|
<0.001 |
| No | 95.5% | 1 | 1 | 1 | |||
| Yes |
67.9% |
9.08 (4.41–18.7) |
|
3.95 (1.71–9.14) |
|
4.62 (2.09–10.2) |
|
| Deep stromal invasion |
|
|
<0.001 |
|
0.4 |
|
|
| No | 91.1% | 1 | 1 | ||||
| Yes |
67.4% |
4.47 (2.73–7.30) |
|
1.29 (0.71–2.35) |
|
|
|
| Large tumour |
|
|
<0.001 |
|
0.06 |
|
0.025 |
| No | 82.9% | 1 | 1 | 1 | |||
| Yes | 62.3% | 2.76 (1.82–4.20) | 2.36 (0.98–2.36) | 1.64 (1.06–2.52) | |||
Abbreviations: AC=adenocarcinoma; AS=adenosquamous; 95% CI=95% confidence interval; HR=hazard ratio; LVSI=lymphovascular space invasion; SCC=squamous cell carcinoma; 5-yr (%)=5-year disease-free survival rate.
Cox proportional-hazards regression test for multivariate 1 (with all variables entered) and multivariate 2 (conditional backward method). P-value for univariate, log-rank test.